Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns

The experimental drug lecanemab shows “potential” as an Alzheimer’s disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with certain serious adverse events.